Page 67 - GALENIKA MEDICAL JOURNAL

16. Jiang H, Jiang Y, Ma H, Zeng H, Lv J. Effects of rivaroxaban and warfarin 28. Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF.
on the risk of gastrointestinal bleeding and intracranial hemorrhage All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin
in patients with atrial fibrillation: Systematic review and meta-analysis. in the Primary Treatment of Venous Thromboembolism. Thromb
Clin Cardiol. 2021 Sep;44(9):1208-15. Haemost. 2018 Sep;118(9):1637-45.
17. Chen X, Huang W, Sun A, Wang L, Mo F, Guo W. Bleeding risks with 29. Liang B, Liang Y, Zhao LZ, Zhao YX, Gu N. Rivaroxaban for
novel oral anticoagulants especially rivaroxaban versus aspirin: a meta- cancer-associated venous thromboembolism. Sci Prog. 2021 Apr-
analysis. Thromb J. 2021 Oct 2;19(1):69. Jun;104(2):368504211012160.
18. US FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein 30. Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ, Coleman CI.
Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction Effectiveness and safety of rivaroxaban compared with low-molecular-
in the Risk of Recurrent DVT and PE Following Initial Therapy. Pfizer. weight heparin in cancer-associated thromboembolism. Blood Adv.
2014. 2016. 2020 Sep 8;4(17):4045-51.
19. Karathanos C, Nana P, Spanos K, Kouvelos G, Brotis A, Matsagas M, et 31. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et
al. Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: al; Caravaggio Investigators. Apixaban for the Treatment of Venous
A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr
Disord. 2021 Nov;9(6):1568-76.e1. 23;382(17):1599-607.
20. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; 32. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS.
AMPLIFY Investigators. Oral apixaban for the treatment of acute Risk of a thrombotic event after the 6-week postpartum period. N Engl J
venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. Med. 2014 Apr 3;370(14):1307-15.
21. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; 33. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N
AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous Engl J Med. 2008 Nov 6;359(19):2025-33.
thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708.
34. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd.
22. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman Trends in the incidence of venous thromboembolism during pregnancy
MV. Effectiveness and safety of novel oral anticoagulants as compared or postpartum: a 30-year population-based study. Ann Intern Med.
with vitamin K antagonists in the treatment of acute symptomatic 2005 Nov 15;143(10):697-706.
venous thromboembolism: a systematic review and meta-analysis. J
Thromb Haemost. 2014;12(3):320-8. 35. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-
Lundqvist C, Cífková R, De Bonis M, et al; ESC Scientific Document
23. Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, et al. Group. 2018 ESC Guidelines for the management of cardiovascular
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165-241.
Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Thromb Haemost. 2018 Nov;118(11):1951-61. 36. Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-
Kadir R. Management of direct oral anticoagulants in women of
24. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, childbearing potential: guidance from the SSC of the ISTH. J Thromb
Shah ND. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban Haemost. 2016 Aug;14(8):1673-6.
for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest.
2016 Dec;150(6):1302-12.
25. Tepper PG, Mardekian J, Masseria C, Phatak H, Kamble S, Abdulsattar Konflikt interesa: Nema
Y, et al. Real-world comparison of bleeding risks among non-valvular
atrial fibrillation patients prescribed apixaban, dabigatran, or Primljeno: 19. 01. 2023.
rivaroxaban. PLoS One. 2018 Nov 1;13(11):e0205989.
Prihvaćeno: 18. 02. 2023.
26. Chen X, Huang W, Sun A, Wang L, Mo F, Guo W. Bleeding risks with Onlajn: 01. 03. 2023.
novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-
analysis. Thromb J. 2021 Oct 2;19(1):69.
27. Wallvik N, Renlund H, Själander A. Bleeding risk in patients with venous
thromboembolic events treated with new oral anticoagulants. J Thromb
Thrombolysis. 2021 Jul;52(1):315-23.

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(5):61-65. 65